c-Met is a chimeric antigen receptor T-cell target for treating recurrent nasopharyngeal carcinoma

Huo, Qingqing; Lv, Jiang; Zhang, Jianzhong; Huang, Haiqiong; Hu, Huayong; Zhao, Yaoxin; Zhang, Xinrui; Wang, Yingqi; Zhou, Yunyun; Qiu, Junchao; Ye, Yanmei; Huang, A. B.; Chen, Yanhong; Qin, Le; Qin, Dajiang; P, Li; Cai, Gang

doi:10.1016/j.jcyt.2023.06.004

Search citation statements

Order By: Relevance

Paper Sections

Select...

Met As a Target For Cellular Immunotherapy1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MET-CAR-T cells have been evaluated for hepatocellular, renal, and nasopharyngeal carcinomas [ 110 , 111 , 112 ]. The application to hepatocellular carcinomas has been refined by using a third-generation CAR, i.e., a construct that includes multiple co-stimulatory domains [ 113 ].…”

Section: Met As a Target For Cellular Immunotherapymentioning

confidence: 99%

MET Oncogene Targeting for Cancer Immunotherapy

Lombardi,

Sangiolo,

Vigna

2024

IJMS

View full text Add to dashboard Cite

The MET receptor is one of the main drivers of ‘invasive growth’, a multifaceted biological response essential during embryonic development and tissue repair that is usurped by cancer cells to induce and sustain the malignant phenotype. MET stands out as one of the most important oncogenes activated in cancer and its inhibition has been explored since the initial era of cancer-targeted therapy. Different approaches have been developed to hamper MET signaling and/or reduce MET (over)expression as a hallmark of transformation. Considering the great interest gained by cancer immunotherapy, this review evaluates the opportunity of targeting MET within therapeutic approaches based on the exploitation of immune functions, either in those cases where MET impairment is crucial to induce an effective response (i.e., when MET is the driver of the malignancy), or when blocking MET represents a way for potentiating the treatment (i.e., when MET is an adjuvant of tumor fitness).

show abstract